Globus Medical GMED NYSE · Healthcare · United States
$68.57 -2.77% -$1.96
Summary
83 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 28% a year over the last 3 years.
- Out of every 100 USD of revenue, 18 USD is left as net profit.
- It holds more cash than debt: $441.3M against $107.6M.
- The share price is below the Bulios Fair Price.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 16.3 USD for 1 USD of yearly profit. Over the last five years it was 54.6 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 30% a year over 5 years. Over the last 3 years it grew by 42% a year. For the next fiscal year analysts expect revenue to grow by 5.5%. Earnings per share grew by 28% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 30 USD
- Research and development 5.8 USD
- Sales and administration 42 USD
- Taxes and other 4.4 USD
- Net profit 18 USD
Net profit, industry median (Medical - Devices) 7.2 USD
Out of every 100 USD of revenue, 18 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 26
- Hold 10
- Sell 1
Today's price within the analysts' price targets
The average target of $95.13 is 39% above today's price. 70% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Spine 94%
- Emerging Technology 6.1%
By region
- UNITED STATES 100%
Spine brings in 94% of revenue. Emerging Technology grew fastest, by 40% a year.
Segments in detail